View Post

Deep learning provides a better estimate of breast cancer risk

In Clinical Studies News by Barbara Jacoby

Source: Radiological Society of North America From: news-medical.net Compared with commonly used clinical risk factors, a sophisticated type of artificial intelligence (AI) called deep learning does a better job distinguishing between the mammograms of women who will later develop breast cancer and those who will not, according to a new study in the journal Radiology. Researchers said the findings underscore …

View Post

What Do BRCA and Lynch Syndrome Have in Common?

In In The News by Barbara Jacoby

By: Georgia Hurst From: curetoday.com/ A previvor analyzes the similarities and overlaps between living with Lynch syndrome and a BRCA mutation. A few years ago, Karen Malkin-Lazarovitz, founder of the BRCA Sisterhood on Facebook, reached out to me and asked me if I would be an administrator for the group. The BRCA Sisterhood is the largest BRCA Facebook support group …

View Post

PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC

In Clinical Studies News by Barbara Jacoby

Source: PharmAbcine From: prnewswire.com PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Ethics Committee (HREC) clearance to commence the Phase II combination trial of olinvacimab, PharmAbcine’s anti-VEGFR2 antibody, and KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 molecule, for the treatment of metastatic Triple-Negative Breast Cancer (mTNBC) in …

View Post

Pathogenic Variant Frequency in Late-Onset Breast Cancer May Inform Future Screening Practices

In In The News by Barbara Jacoby

By: Audrey Sternberg From: cancernetwork.com Data collected from several large studies of women with breast cancer over the age of 65 years at diagnosis show how frequently certain known pathogenic variants occur in different patient subsets. An analysis of data from population-based studies including over 25,000 women with breast cancer who were diagnosed over the age of 65 years suggests …

View Post

JCRI Discovers the Mechanism using Canady Helios™ Cold Plasma to Induce Cell Death in Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: businesswire.com The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI), announced today that they have discovered the mechanism using Canady Helios™ Cold Plasma (CHCP) to induce cell death in breast cancer. Recently accepted for publication in the International Journal of Molecular Sciences, the article “Canady Helios Cold Plasma …

View Post

Savvy Cooperative: People Diagnosed with Breast Cancer to Share About their Experience

In Paid Opportunities For The Cancer Community by Barbara Jacoby

SCREENER SCOPE We’re looking for people who have been diagnosed with breast cancer to share about their experience. Eligibility Criteria: Diagnosis of breast cancer and currently Stage 1 through 3 Verification of diagnosis will be required to participate Patient-reported ECOG score of 0 or 1 Ages 18 years or older Able to read, write, and speak English Have access to …

View Post

THE BREAST CANCER BOOK

In In The News by Barbara Jacoby

From: Johns Hopkins University Press A comprehensive, down-to-earth guide for anyone diagnosed with breast cancer. A Trusted Guide for You and Your Loved Ones By: Kenneth D. Miller, MD, and Melissa Camp, MD, MPH, with Kathy Steligo While life-saving breast cancer treatments and medical advances have increased the likelihood for survival and a long, happy life for many, diagnoses in …

View Post

New compounds offer a two-for-one punch to fight estrogen-sensitive breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Scripps Research Institute From: news-medical.net A set of compounds developed by scientists at Scripps Research in Florida target estrogen-sensitive breast cancer cells in new ways, potentially creating better options for patients with treatment-resistant cancers. “Hormone therapies for breast cancer have been one of the greatest success stories of molecularly targeted medicines. But a significant fraction of patients don’t respond …